P-hydroxylation of phenobarbital: Relationship to (s)-mephenytoin hydroxylation (CYP2C19) polymorphism

Therapeutic Drug Monitoring

Volumn 23, Issue 2, 2001, Pages 115-118

  Hadama, Atsuko ^a,b,c,d   Ieiri, Ichiro ^a,b,c,d   Morita, Toshihiro ^a,b,c,d   Kimura, Miyuki ^a,b,c,d   Urae, Akinori ^a,b,c,d   Irie, Shin ^a,b,c,d   Kaneda, Tatsuya ^a,b,c,d   Mamiya, Kohsuke ^a,b,c,d   Tashiro, Nobutada ^a,b,c,d   Higuchi, Shun ^a,b,c,d   Otsubo, Kenji ^a,b,c,d  

^a KYUSHU UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c Kyushu Clinical Pharmacology Research Clinic   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

CYP2C19; Genetic polymorphism; P hydroxylation; Phenobarbital

Indexed keywords

CYTOCHROME P450 2C19; MEPHENYTOIN; PHENOBARBITAL;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISPOSITION; DRUG EXCRETION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG URINE LEVEL; GAS CHROMATOGRAPHY; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; URINARY EXCRETION; VALIDATION PROCESS; VOLUNTEER;

ADULT; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; HUMANS; HYDROXYLATION; HYPNOTICS AND SEDATIVES; ISOENZYMES; MALE; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; PHENOBARBITAL; POLYMORPHISM, GENETIC;

EID: 0035081487     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200104000-00004     Document Type: Article

References (20)

1. Phenobarbital: Chemistry and biotransformation
2. Effects of felbamate on the pharmacokinetics of phenobarbital
3. Pharmacokinetic interaction between antiepileptic drugs
4. A mechanistic approach to antiepileptic drug interactions
5. CYP2C19 polymorphism effect on phenobarbitone pharmacokinetics in Japanese patients with epilepsy: Analysis by population pharmacokinetics
6. The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction
7. Phenobarbital induces the 2-hydroxylation of desipramine
8. Clinical implications of warfarin interactions with five sedatives
9. Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin
10. The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to ml mutation of CYP2C19 and gene dose
11. Genetic polymorphism of (S)-mephenytoin hydroxylation
12. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population
13. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin
14. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
15. Potential pharmacokinetic interaction between felbamate and phenobarbital
16. Urinary excretion of phenobarbitone and its metabolites in chronically treated patients
17. Roles of cytochrome P4502C9 and P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite
18. Stereoselective metabolism of phenytoin by hepatic microsomes and human CYP2C9 and CYP2C18 expressed in yeast
19. Artemisinin induces omeprazole metabolism in human beings
20. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19